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The bloom-forming dinoflagellate Karenia
brevis (formerly Gymnodiniuim breve) pro-
duces a family of neurotoxins known as the
brevetoxins. These lipid-soluble polyether
toxins, like the ciguatoxins, exert their toxic-
ity by activating voltage-sensitive sodium
channels (1). Human consumption of shell-
fish contaminated with brevetoxins leads to a
nonlethal form of food poisoning (2,3)
called neurotoxic shellfish poisoning (NSP).
During K. brevis blooms, high concentra-
tions of brevetoxins in seawater also affect
fish (4–6), birds, and marine mammals
(7–9), causing massive epizootic events. Fish
kills during K. brevis blooms in the Gulf of
Mexico have been reported in the scientific
literature for over 40 years and known anec-
dotally for over 200 years (10). 
Shellfish exposed to 5 × 103 K. brevis
cells per liter for longer than 24 hr are toxic
to humans (11). Effective water monitoring
programs and shellfish bed closures follow-
ing blooms have allowed few reported cases
of brevetoxin intoxication in humans from
consumption of contaminated shellfish.
However, the actual monitoring of shellfish
by mouse bioassay is slow, with a low
throughput, causing delays in the reopening
of shellfish beds. Development of rapid alter-
native methods for brevetoxin detection in
seafood products is important for those
involved in seafood regulation and the
shellfishing industry as well as for those con-
cerned with public health.
Brevetoxins induce toxicity at very low
concentrations. Therefore, monitoring
requires an analytic procedure having suffi-
cient sensitivity and specificity to detect
toxin at subsymptomatic levels. Because the
matrices in which the toxins are found
(algae, shellfish, body fluid, and seawater) are
diverse and complex, current methods of
quantitative analysis are laborious and
imprecise, requiring many steps of extraction
and partial purification of toxins before
analysis. The difficulties in quantifying
brevetoxins in biologic samples have led us
to pursue a more simple and universal ana-
lytic approach that is applicable to all rele-
vant matrices.
Radioimmunoassays and enzyme
immunoassays are sensitive methods for
quantifying many biologically active small
molecules. During the last 15 years, inten-
sive efforts have developed both polyclonal
(12–23) and monoclonal antibodies (24)
raised against brevetoxins. Additionally,
competitive receptor binding assays using
radiolabeled brevetoxins have shown
promise (25). However, application of these
assays for brevetoxin analysis in complex
matrices such as seafood, seawater, or even
mammalian body fluid has not been com-
pletely successful. 
In this study we describe a quick, sensi-
tive, and accurate ELISA method to quantify
brevetoxins in seafood, seawater, and bio-
logic mammalian fluids. Results indicate that
brevetoxins can be detected accurately at
very low levels in all matrices tested, with
very little sample manipulation. This proce-
dure appears to be a good candidate for an
alternative method for brevetoxin monitor-
ing in shellfish, significantly reduces assay
time when used on homogenates, and could
also be used to confirm exposure to breve-
toxins in suspected cases of neurotoxic shell-
fish poisoning. 
Materials and Methods
All brevetoxins were produced and purified
in this laboratory from cultures of the
Wilson clone of K. brevis. All chemical
reagents, unless otherwise stated, were pur-
chased from Sigma Chemical Company (St.
Louis, MO, USA). HPLC grade solvents
were purchased from Fisher Scientific
(Pittsburgh, PA, USA). All immunochemical
reagents, unless otherwise stated, were pur-
chased from Pierce (Rockford, IL, USA).
Sample Preparation 
Shellfish homogenization procedure. Toxin-
free oysters from North Carolina used in this
study were purchased live at a seafood mar-
ket in Wilmington, North Carolina. We
shucked 100-g portions of toxin-free oyster
meat and combined them in a glass commer-
cial Waring blender without additional
aqueous medium and blended for 5 minutes
at high speed. We used the resulting slurry
for all subsequent preparation of standard
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Articles
We developed a competitive enzyme-linked immunosorbent assay (ELISA) to analyze brevetoxins,
using goat anti-brevetoxin antibodies obtained after immunization with keyhole limpet hemo-
cyanin-brevetoxin conjugates, in combination with a three-step signal amplification process. The
procedure, which used secondary biotinylated antibodies, streptavidine-horseradish peroxidase
conjugate, and chromogenic enzyme substrate, was useful in reducing nonspecific background
signals commonly observed with complex matrices. This competitive ELISA detected brevetoxins
in seawater, shellfish extract and homogenate, and mammalian body fluid such as urine and
serum without pretreatment, dilution, or purification. We investigated the application of this
technique for shellfish monitoring by spiking shellfish meat with brevetoxins and by analyzing
oysters from two commercial shellfish beds in Florida that were exposed to a bloom of Karenia
brevis (formerly Gymnodinium breve). We performed brevetoxin analysis of shellfish extracts and
homogenates by ELISA and compared it with the mouse bioassay and receptor binding assay. The
detection limit for brevetoxins in spiked oysters was 2.5 µg/100 g shellfish meat. This assay
appears to be a useful tool for neurotoxic shellfish poisoning monitoring in shellfish and seawater,
and for mammalian exposure diagnostics, and significantly reduces the time required for analyses.
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spiked homogenate and negative control
homogenates. For analysis of potentially
toxic samples, we substituted field collec-
tions made by Florida Marine Research
Institute staff for nontoxic oyster meat. 
Brevetoxin-spiked standard homogenates.
Nontoxic homogenate prepared as described
above was aliquoted into glass vials (5 g
meat/vial). The samples were spiked with
standard brevetoxins ranging from 0 to 4.0
µg/vial to generate final toxin concentra-
tions of brevetoxins ranging from 0 to 80
µg/100 g shellfish meat in log 2 dilutions.
Spiked samples were incubated for 1 hr at
room temperature and were then homoge-
nized with 200 mL of phosphate-buffered
saline (PBS) for 3 min at high speed on a
commercial blender to generate a final dilu-
tion of the homogenate at 0.025 g/mL. The
homogenates were then frozen at –20°C
until use (26,27).
Shellfish extraction procedure. We pre-
pared homogenates of nontoxic controls
(prepared previously), spiked homogenates,
and authentic field samples for analysis
using two methodologies, one involving use
of the homogenate without solvent extrac-
tion and a second involving homogenization
followed by solvent extraction. Further, we
used two separate solvent extraction proce-
dures: the Association of Official Analytical
Chemists-approved ether extraction or ace-
tone extraction.
For the ethyl ether extraction, we added 5
g NaCl and 1 mL 6 N HCl to 100 g shellfish
homogenate as prepared above; the substances
were mixed and then boiled for 5 min. The
mixture was then transferred to a centrifuge
bottle, combined with 100 mL ethyl ether,
capped, and shaken vigorously for 5 min. The
upper clear green ether phase was carefully
decanted into a separatory funnel and trans-
ferred to a pre-weighed round-bottom flask.
The lower solid phase was extracted three
more times in the same manner. All ethyl
ether extracts were combined and dried down
under a stream of nitrogen gas.
For the acetone extraction, we extracted
shellfish homogenate (100 g) 2 times using
acetone (400 mL). The acetone extracts were
then filtered and reduced in vacuo.
Brevetoxin-spiked extracts. We reconsti-
tuted both extracts (ethyl ether and acetone)
in acetone:methanol (70:30). Aliquots
(extracts equivalent to 5 g meat) were spiked
with a mixture of PbTx-2, PbTx-3, and
PbTx-9 (100:10:1) to generate final toxin
concentrations of 80 µg/100 g shellfish
meat, which is the actual regulatory limit
based on 20 MU/100 g shellfish meat (1
MU = 4.0 µg PbTx) (28). Extracts were then
diluted in 200 mL 0.1M PBS (pH 7.4) to
generate a final dilution of the extract at
0.025 g meat equivalent/mL. 
Brevetoxin-spiked standards in seawater,
human urine, and rabbit serum. We cen-
trifuged Atlantic Gulf Stream seawater at
800 × g for 10 min, decanted the super-
natant solution, and used it for all further
seawater samples. We used seawater, human
urine, and rabbit serum undiluted or diluted
as sample vehicles. Dilutions (1/2, 1/4, 1/8)
were made in PBS containing 0.1% Tween
20 and 0.5% gelatin (PGT). Pure or diluted
samples were then enriched with a mixture
of three brevetoxins (PbTx-2, PbTx-3, and
PbTx-9, 100:10:1, w:w:w). The final toxin
concentration for liquid samples was
between 0.1 and 20 ppb.
Antibodies
We produced and purified the anti-breve-
toxin goat polyclonal antibodies using PbTx-
3-KLH constructs as described previously by
Trainer and Baden (17). 
Enzyme Immunoassay Development 
Flat-bottomed 96-well polystyrene immuno-
plates (NUNC, Maxisorp; Nalge NUNC,
Rochester, NY) were coated with 100 µL of
PbTx-3-bovine serum albumin (BSA) conju-
gate (24,29,30) (250 ng/mL) or BSA alone
by incubating for 1 hr at 25°C or overnight
at 4°C in PBS. After coating, the plates were
washed 3 times with PBS to remove excess
antigen or carrier protein. The remaining
active sites on the plates were blocked by
addition of 250 µL of blocking buffer
(superblock in Tris-buffered saline; Pierce),
followed by three washes with PBS contain-
ing 0.1% Tween 20 (PBS-T). We added
100 µL serially diluted anti-brevetoxin anti-
bodies labeled with horseradish peroxidase
(1:100 to 1:64,000 in PGT) to the each test
well, incubated them for 1 hr at room tem-
perature, and then washed them three times
with PBS-T. Bound antibodies were visual-
ized by the addition of 100-µL o-phenylene-
diamine (OPD; Sigma). To increase the
sensitivity, we also tested two-step and three-
step amplification procedures. We applied
100 µL diluted goat serum (1:100–1:64,000
in PGT) to each well of the plate. We
achieved two-step amplification using the
successive addition of rabbit anti-goat HRP
conjugate (1:10,000 dilution in PGT) with
visualization using OPD. Three-step ampli-
fication employed rabbit anti-goat biotiny-
lated secondary antibody (1:10,000 dilution
in PGT), followed by streptavidin-HRP
conjugate (1:1,000 dilution in PGT) and
OPD for visualization.
For all procedures, we measured the
product absorbance at 492 nm using a
microplate reader (FL600 Microplate
Reader; Bio-Tek Instruments, Winooski,
VT) after a 30-min incubation. Results are
expressed as relative absorbance units. 
We studied the specificity of the antisera
further using a competitive ELISA. The goat
anti-brevetoxin serum (1:4,000 final dilu-
tion) was first preincubated 1 hr at 25°C
with an equal volume of PbTx-2, PbTx-3,
PbTx-9, individually or in a mixture (0–20
ng/mL) as the inhibitor. We then transferred
samples of these mixtures into wells of PbTx-
3-BSA–precoated plates (100 µL/well). After
incubation and washing, the antibodies asso-
ciated with the plates were visualized using
the three-step amplification procedure
described above. The signal obtained in pres-
ence of the inhibitor and absence of the
inhibitor (maximal signal) are referred to as B
and Bo, respectively. Plotting the percent
inhibition (100%–% B/Bo) generated inhibi-
tion curves against the log of the free breve-
toxin concentration.
Brevetoxin Analysis of Seawater and
Mammalian Body Fluid
We incubated 200 µL seawater, human
urine, or rabbit serum enriched with individ-
ual brevetoxins or the mixture described ear-
lier (0.1–20 ng/mL) for 1 hr at 25°C with
the same volume of goat anti-toxin antibod-
ies (1:2,000 dilution with PGT). The anti-
body–sample mixtures were transferred into
wells of PbTx-3-BSA–pre-coated plates (100
µL/well) and incubated for 1 hr. Bound anti-
bodies were visualized using the three-step
amplification procedure described earlier. We
calculated inhibitions as described above and
defined the working range of the assay as the
concentration of brevetoxins inhibiting
between 20% and 80% of the signal.
Analysis of Shellfish Extracts and
Homogenates
For shellfish sample analysis after solvent
treatment, we diluted extracts 2-fold in PGT
to obtain a final concentration of 0.0125 g
meat equivalent/mL. Samples were then seri-
ally diluted (log 2 dilution, 0–1:128) in
shellfish extract buffer (toxin-free shellfish
extract at 0.0125 g meat equivalent/mL) to
maintain matrix composition with the dilu-
tion. We preincubated an aliquot of 200 µL
of each dilution for 1 hr at 25°C with the
same volume of goat anti-brevetoxin anti-
bodies (1:2,000 in PGT).
For homogenate analysis without solvent
extraction, we diluted homogenates 2-fold in
PGT to obtain a final concentration of
0.0125 g meat/mL. Samples were then seri-
ally diluted in shellfish homogenate buffer
(toxin-free shellfish homogenate at 0.0125 g
meat/mL) to maintain matrix composition
along the dilution series. We then incubated
an aliquot of 200 mL of each dilution for 1
hr at 25°C with the same volume of goat
anti-brevetoxin antibodies (1:2,000 in
PGT).
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In both cases, the antibody-sample mix-
tures were transferred into wells of PbTx-3-
BSA–precoated plates (100 µL/well) and
incubated for 1 hr. Bound antibodies were
visualized using the three-step amplification
procedure described earlier. Results were
expressed as percent inhibition. 
Receptor binding assays were conducted
as per Van Dolah et al. (25). We dissolved
shellfish extracts in 2 mL acetone (100%), of
which 1 mL was dried down and resus-
pended in a HEPES binding buffer (50
mM, pH 7.4). We performed competitive
binding assays in 96-well polystyrene plates
(25). PbTx-3 competition curves were gen-
erated using 35 µL [3H]PbTx-3 (10 nM), 35
µL unlabeled PbTx-3 (10–6–10–11 M), and
140 µL synaptosome preparation (25). For
unknowns, we added 35 µL extract in bind-
ing buffer in place of unlabeled PbTx-3. The
plates were then incubated for 1 hr at 4°C.
After incubation, the mixtures were filtered
onto Unifilter-96 GF/B filterplates (Packard
Instruments, Perkin-Elmer, Boston, MA).
Liquid scintillation cocktail was added to
each well (30 µL Microscint 20; Packard),
and the plates were counted using a
TopCount Microplate Scintillation Counter
(Packard). Competition curves were created
and unknowns determined using GraphPad
Prism (version 3.0; GraphPad Software,
Inc., San Diego, CA).
Analysis of Field Samples
Two oyster collections (samples 2 and 3;
each > 100 g of oyster meat) were made by
the Florida Marine Research Institute, the
organization charged with shellfish analysis
in Florida, in December 2000 after a bloom
of K. brevis. An additional sample of the
same species (sample 1) was acquired at the
same time from a nonexposed area in North
Carolina. Mouse bioassays were conducted
on ether extracts of each of these three sam-
ples at the Florida Marine Research Institute
as per the FDA-approved protocol (27).
Residual oyster meat was used for ELISA
and receptor binding analysis, whereby the
oyster meat was defrosted and aliquoted
into two portions: One portion was
extracted with acetone and the other used as
homogenate. 
Results
ELISA Development 
One limiting factor when using goat serum
polyclonal antibodies to detect brevetoxins by
ELISA has been the nonspecific binding of
antibodies to nontarget antigens in direct
ELISAs. The indirect, competitive ELISA
presented here circumvents this problem
while retaining high sensitivity. To develop
this competitive assay, we varied the antibody
concentration and the number of amplifica-
tion steps to find the best combination
resulting in high sensitivity while maintain-
ing a low background signal (Figure 1). A
problem specific to shellfish sampling and
quantification for brevetoxins concerns the
current necessity to employ solvent extrac-
tion before analysis. The homogenate assay
circumvents the need for solvent extraction
and thereby shortens the time necessary to
complete a test. Taken together, these two
modifications produce a test that requires
half the time and reduces background non-
specific noise.
ELISA plates first sensitized with a pro-
tein-brevetoxin conjugate (BSA-PbTx-3) or
the protein alone (BSA) provide, respec-
tively, a specific and a nonspecific binding
matrix for goat anti-brevetoxins antibodies.
Anti-brevetoxins antibodies at increasing
dilution incubated in wells of the sensitized
plates were successful in quantitative detec-
tion using all three signal amplification
procedures described in “Materials and
Methods.”
As shown in Figure 1, a serum dilution
factor of 4,000 reduces nonspecific back-
ground signal, regardless of the amplification
method. However, at the same serum dilu-
tion factor, the three-step amplification pro-
cedure produced the highest specific signal
(and hence greatest sensitivity) with BSA-
PbTx-3 target antigen. We selected these
conditions (serum dilution factor of 4,000
coupled to the three-step amplification pro-
cedure) to assess further the capacity of the
antibodies to recognize brevetoxins in solu-
tion or suspension using a competitive
ELISA format. 
Competitive experiments performed
using three different brevetoxins (PbTx-2,
PbTx-3, and PbTx-9) alone or in mixture-
produced the same inhibition curves (Figure
2). Although this result is not unexpected
given the epitopic recognition of the H-K
ring system (identical in each), it is nonethe-
less important to establish for regulatory
purposes. We observed maximum (100%)
inhibition when the total toxin concentra-
tion in the preincubation buffer was ≥ 5
ng/mL. 
Matrix Effects
Various factors such as salinity, pH, and
lipids modify antigen/antibody interactions
in ELISA, making detection of specific sub-
stances in biologic samples difficult. In this
study, we tested several different matrices
(seawater, human urine, rabbit serum, and
seafood) using the three-step amplification
procedure described earlier, and none
appeared to significantly hamper detection
(Figures 3 and 4). 
Liquid matrices. Seawater, urine, and
rabbit serum used unmodified or diluted in
buffer (PBS), and enriched with varying
quantities of PbTxs before analyses, led to
results more favorable than those obtained in
pure buffer. As shown in Figure 3, the
nature of the samples did not modify the
recognition of brevetoxins by the antibody,
evidenced by the identical inhibition curves
for biologic matrices and buffer controls.
The working range of the assay was 0.2–2
ng/mL for diluted and undiluted samples of
seawater, urine, and rabbit serum. 
Application to seafood matrices. Potential
shellfish matrix effects were also a concern of
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Figure 1. Influence of amplification procedure on
signal specificity in direct ELISA. Toxin-protein
conjugates (BSA-PbTx, 250 ng/mL in PBS) or con-
trol (BSA, 250 ng/mL PBS) were adsorbed to plas-
tic wells of immunoplates before blocking. Diluted
serum or anti-brevetoxins horseradish peroxidase
antibodies were incubated on the plate and pres-
ence of immobilized antibodies was revealed
using 3 different amplification procedures (n = 3,
error bars indicating ± SD). An arrow points to the
serum dilution factor (4,000) that produced a non-
detectable background signal (BSA) and a sensi-
tive specific signal (BSA-PbTx) with the
three-step amplification procedure. 
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Figure 2. Competitive inhibition of goat antibody
binding to BSA-PbTx-coated plates by free breve-
toxins. Toxin-protein conjugates (BSA-PbTx, 250
ng/mL in PBS) were adsorbed to immunoplates
before blocking. Antibodies (1/4,000 in PGT) in
presence of PbTx-2, PbTx-3, PbTx-9 or a mixture
of the three toxins (100:10:1) were incubated on
the plate and after washing steps, immobilized
antibodies were revealed using the three-step
procedure. Results are expressed as inhibition
percent from control (n = 2, error bars within sym-
bols size; in all cases SD was < 5% of the value). 
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this study. Nontoxic shellfish extracts and
homogenates spiked with brevetoxins
showed identical ELISA responses to buffer
spiked with the same amount of brevetoxins
(Figure 4). In all cases, signal inhibition was
correlated with brevetoxin concentration
with no dampening of response. Brevetoxins
in shellfish extracts, homogenate, or ELISA
buffer exhibited 100% signal inhibition at
toxin concentrations of 5 ng/mL and greater,
each with the same working range. Absence
of matrix effects provides a significant
opportunity to reduce the time required to
measure brevetoxins in shellfish without sac-
rificing precision or accuracy. 
An earlier study demonstrated that
brevetoxin recovery from shellfish is affected
by the solvent used to perform the extraction
(31). To define the best strategy for breve-
toxin monitoring in shellfish, we spiked oys-
ter meat with brevetoxins before extraction
by ethyl ether or acetone or simply homoge-
nization in buffer. Analysis of homogenates,
extracts, and buffer measured by ELISA
analysis and compared to the original
amount of toxins incubated with the shell-
fish meat showed that acetone extraction
produced a total recovery of the toxins
whereas ethyl ether extracted only 25% of
the amount present (Figure 5). Brevetoxin
signals from acetone extracts were identical
to those from spiked homogenate. Hence,
brevetoxin analysis by ELISA can be con-
ducted on both shellfish homogenates and
shellfish acetone extracts with equivalent
results, whereas the samples analyzed using
ether extracts consistently underestimated
the total amount of toxin present.
Two oyster samples (samples 2 and 3)
collected by regulatory personnel from
waters exposed to the K. brevis bloom were
deemed unsafe for human consumption
based on the mouse bioassay results per-
formed by the Florida Marine Research
Institute, whereas a control sample from an
unexposed area (sample 1) was found to be
safe by the mouse bioassay (Figure 6A).
ELISA analysis of homogenates and acetone
extracts of these same samples showed the
presence of brevetoxins in samples 2 and 3
while sample 1 was toxin-free (Figure 6B).
Both samples that had greater than the regu-
latory limit of brevetoxins according to the
mouse bioassay (samples 2 and 3) also
showed high levels of brevetoxins by ELISA
and receptor binding assay (RBA). There
were no differences in ELISA-measured
brevetoxin concentrations between shellfish
homogenates and acetone extracts, indicat-
ing that a simple homogenization of shellfish
meat is adequate for quantitative brevetoxin
monitoring. RBA analysis showed a very
good correlation with the brevetoxin con-
centrations determined by ELISA (Figures
6B, 6C). 
Discussion
Enzyme immunoassays are used widely in
both clinical and research fields because they
are rapid, simple, accurate, and specific.
They are also a cost-effective way to quantify
many biologically important molecules such
as steroids (32), peptides, and nucleic acids
(33,34). However, the assays require specific
antibodies for an epitope on the analyte that
does not change within toxic forms of the
analyte. Tests also require matrix adaptation
especially for rare and low-molecular-weight
lipid haptens such as hormones, drugs, and
marine phycotoxins that may be masked by
interfering substances in the matrix. The
polyclonal antibodies used in the present
study have been characterized as to their epi-
topic recognition of the H-K ring region of
the brevetoxin type 2 molecule (20,21).
These latter antibodies were first incorpo-
rated into radioimmunoassays (12) and then
into enzymatic immunoassays (17), both of
which have shown high affinity for brevetox-
ins. The above assays were effective in
detecting brevetoxin in K. brevis cells and/or
in buffer (16,18). 
Brevetoxins are found in a variety of
sample types in nature, ranging from seawa-
ter to mammalian body fluids that often
cause high background noise when using tra-
ditional ELISAs and RIAs. Assays that have
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Figure 4. Comparison of the brevetoxin analysis
performance in enriched oysters matrices.
Immunoplates were sensitized with toxin-protein
conjugates (BSA-PbTx, 250 ng/mL in PBS) before
blocking the remaining active site. Antibodies
were mixed with diluted samples (oyster
homogenate, oyster acetone extract, oyster ether
extract, and buffer) enriched with varying amount
of brevetoxins, and then incubated on plates.
Immobilized antibodies were visualized as previ-
ously described. Results are expressed as per-
cent inhibition from control; each point represents
the mean of duplicate determination with error
bars indicating ± SD.
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Figure 3. Brevetoxin determination in seawater (A), serum (B), and urine (C) at different dilutions by competitive ELISA. Toxin-protein conjugates (BSA-PbTx, 250
ng/mL in PBS) were adsorbed to immunoplates before blocking. Antibodies were mixed with pure or diluted samples spiked with various amounts of PbTx-3 and
then incubated on plates. Results are expressed as percent inhibition from control (n = 2, ± SD).
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Figure 5. Brevetoxin recovery in shellfish ether
extract, acetone extract, homogenate, and buffer
assessed by ELISA. ELISA buffer (1 mL) and oys-
ter meat (1 g) were spiked with 800 ng PbTx-9, -3,
and -2 (1:10:100) and incubated 1 hr at room tem-
perature. Shellfish meat was then extracted with
ether or acetone or homogenized in buffer.
Brevetoxin concentrations were determined by
ELISA analysis, and results are expressed as per-
cent recovery = 100 × (brevetoxins concentration
measured by ELISA/brevetoxins added by spiking)
(n = 2 with error bars indicating ± SD).
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attempted to use direct analysis in matrices
have previously failed. The format in the
present study circumvents matrix problems
and nonspecific color development by
employing a competitive assay. The success
of the assay is accomplished by preincuba-
tion of samples with antibody before addi-
tion to microtiter plates.
The goat antibodies used in this study
have a high affinity for brevetoxin (10–9 M).
With the three-step amplification procedure,
the competitive ELISA can be conducted
with limited amounts of specific anti-breve-
toxins antibodies. The working range of the
assay was between 0.2 and 2 ng/mL, a level of
sensitivity one order of magnitude better than
HPLC-UV detection limit (35). Unlike
HPLC analysis, the competitive ELISA does
not differentiate among type-2 brevetoxins
(PbTx-2, PbTx-3, PbTx-9) but does recog-
nize all of these toxin substructures, consistent
with the earliest observation made with poly-
clonal and monoclonal antibodies (21,24).
With synthetic brevetoxin analogues, the
antibodies showed epitopic specificity for the
H-K ring part of the molecule, the essential
binding region for all type-2 brevetoxins
(20,21). Type-2 brevetoxins account for
90–95% of the toxins produced in a breve-
toxic bloom and all toxic forms possess the
intact H-K ring system. Therefore, the com-
plex matrix samples were spiked with a mix-
ture of PbTx-2, PbTx-3, and PbTx-9 in the
ratio found in cultured K. brevis and repre-
sent a likely spectrum of potential human
toxicants.
Using a direct ELISA method, we found
that the sample composition (e.g., seawater,
urine, serum, or shellfish extract) modified the
antigen/antibody interaction. At low dilution,
the presence of components in the biologic
samples reduced the binding of the antibodies
to the antigen, as has been shown previously
for brevetoxins in shellfish extracts (18) and for
domoic acid in urine (36). To measure breve-
toxins and minimize matrix effects, we per-
formed competitive experiments varying toxin
concentration in the sample by dilution and
comparing them with the results from matrix
controls without toxin. In all cases, 5 ng/mL of
brevetoxin induced a total inhibition of the sig-
nal, the working range of the assay was
between 0.2 and 2 ng/mL, and analysis can be
performed without dilution and/or purification
of sample (seawater, serum, and urine) (Figure
3). Thus a substantial time element is reduced
by enabling direct measurement of brevetoxins
in biologic liquids.
The limit of toxicity in humans upon
ingestion of shellfish is presumed to be 20
MU/100 g shellfish meat or about 80 µg
PbTx-2. This assay provides the potential to
evaluate more closely the actual toxin con-
centrations that may lead to human illness.
Previous studies have shown that in
rodents, 15–28% of the brevetoxins are
excreted in urine after administration
(37,38). Assuming the same depuration rate
in humans, 120–240 ng of toxin would be
expected to be found in 10 mL of human
urine if 80 µg toxin had been ingested. The
competitive ELISA sensitivity clearly would
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Figure 6. Comparison of brevetoxin determination in oyster samples from Florida by mouse bioassay (A),
ELISA analysis of acetone extract and homogenates (B), and receptor binding assay of acetone extracts
(C). Toxic field samples (sample 2 and 3) were collected in December 2000 after a bloom of K. brevis.
Sample 1 (control) was collected at the same time from a nonexposed area. Mouse bioassay results were
obtained according to the standard protocol for shellfish monitoring (n = 3; error bars indicate ± SD).
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Figure 7. Time schedule for ELISA analysis versus mouse bioassay.
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permit its use in diagnostic cases. The only
reported case of brevetoxin detection in
human urine of intoxicated people involved
brevetoxin concentrations of 83–235 ng/mL
in the urine of two children who had con-
sumed contaminated shellfish (39). The
competitive ELISA could have been used to
measure brevetoxins in this study quickly
and accurately, without sample pretreatment
or dilution.
These results are encouraging for the
development of a new method to replace the
mouse bioassay. In the present study, we
compared different formats of the assay for
brevetoxin analysis in seafood matrices, analy-
sis of homogenates, and analysis of shellfish
extracts. Recently, a thorough comparison of
different extraction processes indicated that
the recovery of brevetoxins from shellfish
depends on the extraction protocol used (25).
Results from the present study clearly
demonstrate that the presence of shellfish
homogenate or shellfish extracts does not
interfere with the performance of the assay
(Figures 3 and 4). In both matrices, the signal
inhibition correlated with the amount of
toxin present in the sample, and no inhibition
was observed when toxins were absent. The
working range of the assay, as with all other
matrices, was 0.2–2 ng/mL, corresponding to
0.8–8 µg brevetoxins/100 g shellfish meat
(10–100 times below the national regulatory
limit). The field oyster samples from three
different shellfish beds analyzed by mouse
bioassay, ELISA, and receptor binding assay
showed strong agreement and correctly distin-
guished toxic from nontoxic samples. 
Recent work by Poli et al. (40) has
demonstrated that PbTxs are metabolized in
shellfish and are implicated in shellfish toxic-
ity. At least three derivatives have recently
been identified (40). These compounds pos-
sess the PbTx type-2 backbone but a modi-
fied side chain. The antibodies used in this
study are specific for the last H-K rings of
the PbTx type-2 backbone excluding the
side chain (15), so these antibodies will also
recognize PbTx metabolites. As shown on
Figure 6 and also reported by others (31),
ether extraction is an inefficient method for
extracting brevetoxins from shellfish meat,
further increasing the value of measuring
total toxin backbone in shellfish homogenate
by ELISA. The presence of these metabolites
may cause underestimation of the true toxic-
ity of shellfish if only ether extracts are ana-
lyzed. Being sensitive, rapid, and accurate
with a simple shellfish sample homogenate,
this in vitro assay appears to be a good candi-
date for rapid shellfish monitoring. 
The time required for analysis of shellfish
samples (Figure 7) has been a perplexing
problem for regulatory officials. Many varia-
tions for rapid assays have been proposed,
but most require extensive preparation of the
food source of interest. As has been aptly
pointed out time and again, “if the sample
preparation time cannot be reduced, rapid
assays present no true advantage over the
presently available assays” (41). Aside from
collection of the samples, preparation
including solvent extraction represents the
principal impediment to rapid analysis. 
The industry concurs that if a particular
method takes 6–8 hr to produce a sample
suitable for testing, there is little value in the
subsequent test format, even if it takes an
additional 30 sec to complete. The fact
remains that preparation of the sample rep-
resents the principal time constraint, as has
been the case for Florida red tide brevetoxin
testing since the 1950s. Samples are
shucked, homogenized, and extracted with
ether. The ether is dried, the extract redis-
solved in vegetable oil, and injected into ani-
mals. Animals are observed for 6 hr (a
distinct improvement over the previous
24-hr observation time). However, even in
its present regulatory form, only a limited-
size set of analyses can be examined by
mouse bioassay in a 24-hr period.
The shucking and homogenization
aspects remain in the present assay. But all of
the subsequent steps have been replaced by a
6-hr three-step procedure that overall
decreases the amount of time required for
analysis by 12 hr. The sample size also has
been diminished substantially, allowing
many more samples to be handled at one
time. This in effect provides for multiple
parallel analyses of different (or replicate)
samples. 
Thus, the present assay, being useful and
applicable to crude homogenate samples,
addresses the principal time constraint to
Florida Red Tide toxin testing—sample
preparation time. Coupled with the exquisite
sensitivity of the ELISA amplification tech-
nique, this represents the most significant
advance in the analysis of suspect brevetoxic
seafood since the radioimmunoassay in 1984.
In conclusion, this competitive ELISA is
a very sensitive method for detecting breve-
toxins in complex matrices. It is very power-
ful tool not only for reducing the incidence
and improving the diagnosis of brevetoxin
intoxication of human and other animals,
but also for studying transfer and impact of
brevetoxins in the environment.
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